Keyword Tag Sort by

Categories: Leukemia Green Tea CLL Chronic lymphocytic leukemia

Green Tea Extract Shows Promise in Leukemia Trials

ROCHESTER, Minn. — Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea. The trial determined that patients with chronic lymphocytic leukemia (CLL) can tolerate the chemical fairly well when high doses are administered in capsule form and that lymphocyte count was reduced in one-third of participants. The findings appear today online in the Journal of Clinical Oncology.

"We found not only that patients tolerated the green tea extract at very high doses, but that many of them saw regression to some degree of their chronic lymphocytic leukemia," says Tait Shanafelt, M.D., Mayo Clinic hematologist and lead author of the study. "The majority of individuals who entered the study with enlarged lymph nodes saw a 50 percent or greater decline in their lymph node size."

CLL is the most common subtype of leukemia in the United States. Currently it has no cure. Blood tests have enabled early diagnosis in many instances; however, treatment consists of watchful waiting until the disease progresses. Statistics show that about half of patients with early stage diseases have an aggressive form of CLL that leads to early death. Researchers hope that EGCG can stabilize CLL for early stage patients or perhaps improve the effectiveness of treatment when combined with other therapies.

The research has moved to the second phase of clinical testing in a follow-up trial — already fully enrolled — involving roughly the same number of patients. All will receive the highest dose administered from the previous trial.

These clinical studies are the latest steps in a multiyear bench-to-bedside project that began with tests of the green tea extract on cancer cells in the laboratory of Mayo hematologist Neil Kay, M.D., a co-author on this article. After laboratory research showed dramatic effectiveness in killing leukemia cells, the findings were applied to studies on animal tissues and then on human cells in the lab. (See "Green Tea and Leukemia" in Discovery's Edge magazine.)

In the first clinical trial, 33 patients received variations of eight different oral doses of Polyphenon E, a proprietary compound whose primary active ingredient is EGCG. Doses ranged from 400 milligrams (mg) to 2,000 mg administered twice a day. Researchers determined that they had not reached a maximum tolerated dose, even at 2,000 mg twice per day.

The study was sponsored by Mayo Clinic, the CLL Global Research Foundation, CLL Topics (including contributions by individual CLL patients) and the Commonwealth Foundation for Cancer Research. Medication for the study was provided by Polyphenon E International. Others on the research team were Timothy Call, M.D.; Clive Zent, M.D.; Betsy LaPlant; Deborah Bowen; Michelle Roos; Charla Secreto; Asish Ghosh, Ph.D.; Brian Kabat; Diane Jelinek, Ph.D.; and Charles Erlichman, M.D., all of Mayo Clinic; and Mao-Jung Lee, Ph.D., and Chung Yang, Ph.D., both of Rutgers University.

VIDEO ALERT: Additional audio and video resources, including comments by Dr. Shanafelt describing the research, are available on the Mayo Clinic News Blog.

Contact: Robert Nellis, 507-284-5005 (days), 507-284-2511 (evenings),

Source: Mayo Clinic, Mayo Foundation for Medical Education and Research

Related News:

Leukemia Patients Remain in Remission More Than Two Years After... 10 December 2012, 05:58
University of Pennsylvania Researchers Report on Results of Trial in 12 Patients, Including Two...

IU researchers identify protein target that could lead to therapies... 24 July 2012, 14:12
INDIANAPOLIS -- Researchers at the Indiana University School of Medicine have identified a...

Tea Drinkers at Greater Risk of Prostate Cancer 19 June 2012, 02:56
Men who are heavy tea drinkers may be more likely to develop prostate cancer, according to...

NIH Study Finds Childhood CT Scans Linked to Leukemia and Brain... 12 June 2012, 05:14
Children and young adults scanned multiple times by computed tomography (CT), a commonly used...

An Achilles Heel of Aml: Gene Mutations Play Critically Important... 16 April 2012, 09:24
A Promising Development for New Treatments.The key to treating one of the most common types of...

Scientists discover how to beat resistance to standard leukaemia drug 9 December 2011, 13:23
Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a...

Scientists demonstrate potential new treatment for most common form... 3 October 2011, 08:29
A team lead by Cancer Research UK scientists have shown that a potential new drug could treat...

Researchers Uncover Gene Associated With Blood Cancers 27 September 2011, 07:23
New genetic insights could facilitate screening for mutation.A genomic study of chronic blood...

Gene Test Predicts Leukaemia Survival 1 June 2011, 04:42
Scientists at The Institute of Cancer Research (ICR) have found that a genetic test can be used...

A Gene That Fights Cancer, But Causes It Too 17 May 2011, 06:08
Over-activation of a single gene promotes leukemia, but its loss causes liver cancer.An...